On May 4th, 2023, Esperion Therapeutics Inc. issued a press release regarding their amended complaint against Daiichi Sankyo Europe GmbH.

Daiichi Sankyo Europe GmbH (“DSE”) disagrees with the claim by Esperion Therapeutics Inc. in that press release, its original complaint, and its amended complaint.
 

We are disappointed by Esperion’s perception of our partnership. Our difference in opinion regarding the matter is solely based on our interpretation of the contractual agreement that was made between our two companies.

DSE will vigorously defend our position in court (where the matter should be addressed) and not otherwise comment publicly on pending litigation.

Press Contact:

Dr. Wolfgang Schiessl

Daiichi Sankyo Europe GmbH

Email: wolfgang.schiessl@daiichi-sankyo.eu

Tel.: +49 151 17147317